NICE Final Appraisal Favors Cost-Effectiveness Of Aromatase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K's National Institute for Health & Clinical Excellence released a final appraisal determination Aug. 11 supporting the clinical benefit of aromatase inhibitors over tamoxifen in primary adjuvant and unplanned switch treatment of early-stage breast cancer
You may also be interested in...
Aromatase Inhibitors Cost-Effective Compared To Tamoxifen, NICE Finds
Although an overall survival advantage has not been shown, the U.K. agency recommends coverage of Arimidex, Aromasin and Femara.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.